Drug Approval | March 11, 2022
USFDA approves Lupin’s Vigabatrin oral solution
The product will be manufactured at Lupin’s facility in Goa, India
The product will be manufactured at Lupin’s facility in Goa, India
Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Transformative closed-loop technology senses the spinal cord's response to stimulation and instantaneously adjusts therapy to sustain durable, optimized treatment
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Launched in 2020, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products by boosting their production and supply through open, non-exclusive licensing agreements
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
The product will be manufactured at Lupin’s facility in Pithampur, India
This has further strengthened its manufacturing presence in the United States of America
Subscribe To Our Newsletter & Stay Updated
